Published Online: July 18, 2017
AJMC Staff
AN INTERIM ANALYSIS OF TWO phase 2 trials has found that trabectedin and lurinectedin demonstrated remarkable activity as single agents in BRCA2-associated metastatic breast cancer, with 33% clinical response with trabectedin and 61% with lurbinectedin.
Results of the analysis were reported in a poster session at the 2017 American Society of Clinical Oncology Annual Meeting.
...